Drug Approval | July 02, 2022
Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
It is a two dose vaccine to be administered intramuscularly at 28 days apart
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Bioresource Technology's state of the art manufacturing facility in Weston, Florida
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
Based on a post hoc analysis, fewer required respiratory interventions
Subscribe To Our Newsletter & Stay Updated
